Sovaprevir tablets
AssigneeAchillion Pharmaceuticals, Inc.
InventorsJennifer Hsing-Chung Chu, Gautam Shah, Avinash Phadke
Life of this patent
Estimating the term…
Abstract
The disclosure includes tablet cores comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), copovidone (PVP-VA), a copolymer of methacrylic acid and ethyl acrylate, or any combination of the foregoing, wherein ratio of Sovaprevir to crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w). The disclosure further includes film coated tables. The disclosure also includes methods of treating HCV with the tablets described herein.
Claims18
A Sovaprevir immediate release composition, comprising an amount of Sovaprevir from about 100 mg to about 400 mg Sovaprevir;
- wherein the composition provides
- an AUC0-72 of about 150 ng·hr/ml to about 2500 ng·hr/ml;
- a mean Cmax of about 20 ng/ml to about 750 ng/ml;
- and
- a mean Tmax of about 0.5 to about 5.0 hr.
A Sovaprevir tablet core, comprising Sovaprevir and a crystal growth inhibitor selected from hydroxypropyl methyl cellulose (HPMC), HPC (hydroxypropyl cellulose), hypromellose acetate succinate (HPMCAS), polyvinyl pyrrolidone (PVP), and copovidone (PVP-VA), or any combination of the foregoing, wherein ratio of Sovaprevir to the crystal growth inhibitor is from about 40:60 (w/w) to about 60:40 (w/w).
Dependencies are inferred from the claim text.